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The goal of this study was to analyze the emergence of treatment standards associated with the 
adoption of anti-HIV drug innovations in the empirical setting of Italian clinical practice. Due to the rapid 
pace of technological change and the initial uncertainty concerning capabilities and indications of new 
treatments, the emergence of standard patterns of care turned out to be far from predictable and 
straightforward. Health providers' links to an international medicine and their internal coordination 
mechanisms were found to be associated with clinical decisions. Effectiveness and health costs of 





Starting from the mid-1990s, the introduction of new powerful drug combinations called 
HAART (Highly Active Antiretroviral Therapy) has revolutionized HIV/AIDS care. HAART 
has radically changed the natural course of HIV infection (Palella et al., 1998), which is rapidly 
becoming a chronic manageable disease. The range of therapeutic alternatives has widened over 
the years and clinical treatment models have been developing as temporal sequences of 
interdependent combination therapies. 
The objective of this study is to investigate the emergence of different treatment patterns after 
the introduction of HAART in the setting of Italian clinical practice. Namely, three research 
issues are addressed. First, we describe the evolution of individual therapeutic paths and the 
emergence of typical treatment patterns in the HAART era. Second, we analyze whether 
structural and organizational characteristics of health providers are related to therapeutic choices. 
Finally, we compare the effectiveness and the efficiency of alternative treatment patterns. 
The empirical work is based on detailed evidence at the patient-level and on original data 
from a large national survey of HIV/AIDS care providers.  
This paper contributes to the literature on medical innovations in several ways. It carefully 
describes the development and nature of treatment standards in which a technological innovation 
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mail: merito@sssup.it. becomes embedded and through which it spreads. To better observe the pace and degree of 
standardization, it focuses on whole individual therapeutic histories instead of single drug 
treatments and, in doing so, it introduces sequence analysis methodology for the study of 
treatment patterns. 
The article proceeds as follows. In Section 2 we introduce the theoretical background on 
adoption of medical innovations and standard setting in clinical practice, and we describe the 
recent evolution of HIV/AIDS care. Section 3 illustrates patient and provider data, whereas the 
methodology adopted in the empirical analysis is explained in Section 4. Study findings are 
presented and discussed in Section 5. Section 6 reports some concluding remarks. 
 
 
2. Innovation and treatment standards in HIV care 
 
2.1. Innovation dynamics in HIV treatments  
 
Classical diffusion theory assumes that innovations are sufficiently well defined for individuals 
to be able to assess their relative advantage, risk, and cost (Geroski, 2000). Actually, as Rogers 
(1995) points out, all innovations carry some degree of uncertainty for the individual, who is 
typically unsure of their results and thus feels a need for social reinforcement in order to adopt 
them. In the case of medical technologies, agreement on capabilities and indications sometimes 
lags well behind the introduction of innovations, which often occurs when the new products or 
procedures are not yet completely formed. Many medical technologies develop as they diffuse, 
in a dynamic manner, with a resulting diffusion pattern different than the classical one, i.e., 
slower and less predictable (Greer, 1981).  
Following the approval of Zidovudine (AZT) for commercial use in the treatment of 
HIV/AIDS in 1987, new antiretroviral agents have been introduced at an increasingly rapid pace. 
During the 1990s, a robust correlation between long-run clinical benefits and short-run changes 
in surrogate endpoints (CD4+ lymphocytes cell count and plasma viral load) was recognized in 
the scientific literature (Shi et al., 1996). Since the mid-1990s, when routine viral load testing 
became available, surrogate markers have been easily observable and it has been possible to 
collect data on new drugs' efficacy without waiting several years for the clinical outcomes to 
occur. In turn, this has made possible the accelerated approval for new drugs based on such 
evidence, which, together with widespread compassionate use programs, implied that initial 
adoption of innovations could occur widely soon after Phase I clinical trials and before much 
efficacy data were gathered (Maguire, 2002).  
Until 1995, other agents belonging to the same pharmacological class of AZT (NRTIs, 
Nucleoside Reverse Transcriptase Inhibitors) were registered; as from 1996, medications of 
other pharmacological classes (PIs, Protease Inhibitors; NtRTIs, Nucleotide Reverse 
Transcriptase Inhibitors; NNRTIs, Non-Nucleoside Reverse Transcriptase Inhibitors) have been 
commercialized. New powerful combination therapies using at least three antiretroviral agents 
were introduced and referred to as Highly Active Antiretroviral Therapy (HAART). These 
advances have been accompanied by the development of more sophisticated diagnostic 
procedures to assess viral load and HIV mutations (more sensitive plasma HIV-RNA level 
assays, phenotypic and genotypic assays), useful in supporting clinicians' decisions about 
therapy administration (Christopherson et al., 1998; Torre and Tambini, 2002).  
  2Due to the rapid changes in HIV treatments and the initial uncertainty concerning their long-
term use, possible side effects, and effectiveness outside of controlled trials in a real world 
setting, in clinical practice HAART adoption may have proceeded in a less straightforward 
manner than expected from its clear superiority with respect to mono and dual therapies. 
 
 
2.2. Scientific knowledge and learning-by-doing in the medical profession 
 
Medical doctors have recently been described as a typical example of a people-centered 
profession, which strongly relies on learning-by-doing as well as on scientific knowledge in 
everyday practice (Foray and Hargreaves, 2003). Physicians build up their expertise through a 
combination of scientific, explicit knowledge and learning-by-doing experience from their work 
with patients. 
The failure of researchers to report consistent findings and to include clinically important 
details diminishes the role of scientific literature in resolving the uncertainty surrounding new 
health technologies. In a study analyzing the receipt and use of medical information by 
practicing physicians in local community hospitals, Greer (1988) finds that local professional 
communities, in spite of their links to an international medicine, are rather closed systems. Most 
clinicians like to see a general trend before they adopt a new technology, and the general trend is 
often the local trend. Local consensus is achieved through a process of personal communication 
regarding risk, benefit and appropriateness; opinion leaders are important actors in this 
assessment.  
The efficacy of triple combination therapy and its superiority with respect to mono and dual 
therapies were first assessed in randomized clinical trials, whose findings were quickly reported 
in a number of specialized academic and technical journals (Hammer et al., 1997; Montaner et 
al., 1998). Thereafter, it has been explored in numerous multi-center observational studies, with 
the intent to analyze different features of alternative antiretroviral regimens in clinical daily 
practice (Mocroft et al., 2003; Palella et al., 1998). Due to multi-center cohort studies, clinical 
advancements spread and inform therapeutic decisions among practitioners in a large number of 
even small treatment providers (wards/clinics).  
In addition to performing clinical research, physicians may get medical information from 
meetings, workshops and conferences that periodically take place on the subject. These events 
are usually sponsored by pharmaceutical companies, which also play a direct role in 
communicating research findings while marketing their products to doctors. As an aside, it is to 
be noticed that in Italy physicians treating HIV-positive patients cannot be general practitioners: 
antiretroviral drugs may be prescribed only by specialized virologists, working in hospital 
infectious diseases wards/clinics and forming a relatively small and connected community. 
Still, we foresee the idiosyncratic component of physicians' treatment choices in HIV/AIDS 
care to be relevant and lead to high heterogeneity in patient therapeutic patterns. In this setting, 
we try to assess whether specific structural and behavioral features of the health providers (that 
is, the clinical centers) may affect treatment decisions, with particular regard to the influences of 
their links to the international science and internal coordination mechanisms. 
 
  32.3. Characteristics and role of standardization in clinical practice 
 
Throughout its professional history, the medical community has developed standardization based 
on procedures, rules and routines as a powerful tool not only to coordinate the activities of its 
members, but also to cope effectively with the intrinsic uncertainty of clinical practice. Such 
behavioral standards can assist in coordination by helping to align expectations, and can reduce 
measurement and monitoring costs by providing a benchmark against which quality of 
performance can be judged (David, 1987). 
Medical professionals can actually be thought of as information-processing systems that must 
apply a large repertoire of routines to fit widely varying concrete circumstances (Stinchombe, 
1990). Given significant task uncertainty, the particular concrete application of the routines 
requires individual professional judgment (Langlois and Savage, 2001). Since rigid 
standardization of productive routines would be ineffective in health care, along with the 
standardization of professional education, treatment guidelines have been developing over time 
as a general and flexible system of standards, generally accepted among medical practitioners.  
Medical guidelines are systematically revised statements which help physicians select the 
most appropriate interventions in given circumstances, informing providers on optimal 
diagnostic, therapeutic and resource management strategies. Typically issued by national and/or 
international organizations and professional societies widely legitimized by the medical 
community, guidelines reduce uncertainty in clinical procedures and are generally believed to 
lead to an overall improvement of health practices (Andrews and Redmond, 2004). They must be 
developed and constantly updated through a multidisciplinary process that can also involve 
patients' representatives together with medical doctors, other health professionals and health 
service managers (Leape, 1990). 
With the advent of HAART, treatment guidelines have been developed and continuously 
revised by international and national scientific boards and expert panels as reference standards of 
good clinical practice (U.S. Department of Health and Human Services, 1998-2005; British HIV 
Association, 2001-2005; Commissione nazionale AIDS, 2001-2003). These guidelines now 
address all major issues arising in therapy administration - such as treatment goals, initiation and 
discontinuation of therapy, recommended combinations and possible complications, patient 
adherence - summarizing the state of the art in HIV treatment. 
International therapeutic guidelines act as a driving force toward standardization of clinical 
practice in HIV/AIDS care. Nevertheless, their necessary flexibility and lack of enforcement 
power leave room for largely discretional treatment decisions. We wish to investigate whether, 
on the one hand, given the uncertainty that informs all medical culture, this form of 
standardization can be shown to be effective in terms of health benefits and whether, on the other 





3.1. Patient and provider data 
 
ICONA (Italian Cohort Naive Antiretrovirals) is an observational study that recruits HIV-
infected adults naive to antiretroviral therapy. Prospective routine data collection in ICONA 
includes clinical and epidemiological parameters, antiretroviral drug regimens, prophylaxis and 
  4treatment of opportunistic infections, inpatient episodes and death. A previous work evaluated 
retrospectively health costs incurred by the Italian National Health Service (SSN) for hospital 
admissions, drugs and major laboratory exams (Merito et al., 2005).  
The present study was conducted on 2 983 patients of the ICONA cohort, enrolled between 
February 1997 and December 2002 in 55 Italian Infectious Diseases Clinics and subsequently 
starting at least one antiretroviral regimen. Although patients entered the cohort during the whole 
observation period, there were two major rounds of enrolments, the first running from May, 1997 
to the first months of 1998, and the second in 2000, intended to replace the dropouts. 
At the beginning of year 2001 a prevalence study (StuPre), relative to the year 2000, collected 
several data on 168 Italian infectious diseases units providing health services to HIV-infected 
patients. The StuPre survey gathered information on some structural characteristics of the 
clinics/wards interviewed, as well as on their inpatient and outpatient activities. Among the 
clinics surveyed 55 were also participating in the ICONA project, with no geographical or 
dimensional bias with respect to the entire ICONA population. The North of the Country and 
some big cities (Rome, Milan) were overrepresented in both studies, reflecting the epidemiology 
of HIV/AIDS in Italy and the availability of specialized health care services. Providers were all 
operating within public hospitals, since there is no private sector for the treatment of HIV/AIDS 
patients in Italy. Main characteristics of providers included in the ICONA project are 
summarized in Table 1. 
Hospital size ranged from 22 to 2 400 beds, with the majority having more than 600 beds. 
Infectious diseases clinics might offer only ambulatory services (thus having no ward beds) or 
operate quite large inpatient facilities (up to 60 inpatient beds). In 2000, genotypic resistance 
testing assays were still performed in few laboratories; there did not seem to be any correlation 
between the availability of this kind of test (an advanced diagnostic procedure to assess HIV 
mutations) and the provider size. All the clinics were at least mentioned in some publications as 
members of a study group and, indeed, all were participating in at least two multi-center studies. 
 
 
3.2. Individual therapeutic sequences 
 
Based on the frequency of each anti-HIV regimen in our population, characterized by the number 
and class of molecules in the mix, thirteen common pharmacological combinations and one 
residual were selected. Individual therapeutic paths were then obtained for all patients in the 
study, considering the successive antiretroviral therapies, as previously classified, followed by 
each subject from enrolment to death/drop/administrative censoring. A therapy is modified 
whenever one or more drugs are abandoned, added, or substituted. The switch may lead to the 
adoption of a different treatment regimen, or a combination of the same type as the previous one. 
We identified 619 different therapeutic sequences, including up to 13 switches; most patients 
(75.1%) experienced not more than 5 therapy changes.  
A therapeutic switch may have several clinical meanings. Reasons for discontinuing an 
antiretroviral regimen that emerge from the ICONA database range from therapy failure to 
simple therapy updates. More specifically, a drug combination may for instance be changed due 
to clinical, immunological or virological failure, intolerance to drugs and possible side effects, 
development of cross resistances among drugs belonging to the same therapeutic class. But we 
can also find new regimen formulations, without any evidence of failure of the preceding one, 
and therapy simplifications after successful first line regimens. 
  5Table 1 Providers' structural and operational characteristics. 
   N  %  Cum 
Hospital beds        
  <=200 10  18.18  18.18 
  200-600 13  23.64  41.82 
  600-1 000  10  18.18  60.00 
  1 000-1 600  10  18.18  78.18 
  >1 600  5  9.09  87.27 
  N.A. 7  12.73  100.00 
Ward beds        
  <=15 14  25.45  25.45 
  15-25 17  30.91  56.36 
  25-35 17  30.91  87.27 
  >35 7  12.73  100.00 
Genotypic assays        
  In the center's lab  8  14.55  14.55 
  In the hospital's lab  8  14.55  29.09 
  In another hospital  17  30.91  60.00 
  Not performed  19  34.55  94.55 
  Other 3  5.45  100.00 
Phenotypic assays        
  In the center's lab  29  52.73  52.73 
  In the hospital's lab  7  12.73  65.45 
  In another hospital  7  12.73  78.18 
  Not performed  8  14.55  92.73 
  Other 4  7.27  100.00 
Publications (national 
and international)        
  <=10 20  36.36  36.36 
  10-15 14  25.45  61.82 
  >15 13  23.64  85.45 
  N.A. 8  14.55  100.00 
Participation in multi-
center studies        
  <=5 8  14.55  14.55 
  5-10 17  30.91  45.45 
  10-15 13  23.64  69.09 
  >15 9  16.36  85.45 
  N.A. 8  14.55  100.00 
        
   Mean  (Std.Dev.)  Median 
Incidence of HIV 
inpatient episodes   0.320  (0.307)  0.280 
Day Hospital utilization 
rate   0.345  (0.299)  0.295 
 
  6For our purposes, a therapeutic sequence is the crucial unit of analysis, since it allows us to 
summarize the entire patient treatment history and to track the complex interactions between 





4.1. Sequence analysis 
 
Individual therapeutic paths were subjected to optimal alignment so as to generate interval-level 
measures of resemblance between pairs of sequences. The inter-sequence distances resulting 
from this whole sequence analysis methodology were then input to clustering in order to uncover 
common patterns among treatment sequences. 
Optimal alignment (coupled with a standard categorization method) was an appropriate 
analytical technique in this case. Due to the strong heterogeneity of therapeutic sequences in our 
database we needed to categorize past treatment histories, trying to d e t e c t  s o m e  c o m m o n  
patterns, if any. Moreover, the variable of interest - combination therapies - is categorical, but the 
process is not Markovian (and maybe not stationary either): at every point in time clinical 
decisions on what next depends crucially on the entire therapeutic history of a subject. 
Optimal alignment measures the edit distance between pairs of sequences, that is, the 
minimum number of edit operations (insertion, deletion, substitution) on the individual 
characters of the two sequences required to transform one string into the other (Sankoff and 
Kruskal, 1983). Clearly the length of the sequences influences the number of transformations 
required. And in a shorter sequence one substitution is more important than in a longer one. We 
adopted the strategy of standardizing the edit distance by dividing the transformation distance by 
the length of the longer sequence.  
In our computations we allowed an arbitrary weight or cost to be associated with every edit 
operation and implemented the Needleman-Wunsch algorithm (the basic algorithm for sequence 
comparison in the dynamic programming framework that allows for the use of arbitrary 
weights). The weighted edit distance problem becomes that of finding an edit alignment that 
transforms one string into the other with the minimum total cost. We chose a uniform 
insertion/deletion (indel) cost, making insertion and deletion cost the same in all cases, whereas 
we tried different weighting schemes for substitution costs: simple edit distance, where all 
editing operations cost one, was compared with two distance measures derived from structured 
matrices of substitution costs, based either on transition frequencies in the whole ICONA 
population between the codified drug combinations, or on clinical appraisal of inter-therapy 
similarities. Although different substitution cost schemes lead to different sequence distances, 
experimental work (Forrest and Abbott, 1990) indicates that the calculated distances are not 
substantially affected by even fairly strong perturbations in the substitution costs. We also chose 
to scale indel costs with respect to substitution costs, trying different parameter values, as a 
refinement of the alignment distance. 
To uncover actual types of patterns in our therapeutic sequences we employed different 
clustering methods. As is well known, different algorithms for cluster analysis produce slightly 
different solutions. In the present work we used both various agglomerative hierarchical methods 
(single linkage, complete linkage, average linkage and Ward linkage), comparing their relative 




4.2. Regression analysis 
 
To study the impact of various patient and provider characteristics affecting individual treatment 
histories together with technological development, a multinomial logit model was estimated for 
the main therapeutic patterns emerging from the clustering of individual sequences. The choice 
of a multinomial logit specification in our case was justified by two orders of considerations: 
firstly, the outcome variable was categorical and clearly unordered; secondly, we didn't have any 
choice specific attribute (actually, in this case of complex treatment histories it is quite simply 
difficult to figure them out).  
Due to the high heterogeneity of individual sequences, together with a reference path, we 
could clearly identify two comparison patterns of some importance, leaving all other 
idiosyncratic histories, dispersed over a variety of different pathways, in a residual category. The 
relevance of the outcome categories we chose to disentangle was defined both in terms of their 
frequencies in the dataset and the competing standards they represented, given the constraint of 
limiting the overall number of choices to few alternatives (indeed, the number of parameters in 
the multinomial logit proliferates with the number of choices requiring large sample sizes).  
We compared AIDS-free survival and costs among the identified therapeutic pathways. A 
Cox proportional hazards model was estimated to assess the effect on AIDS-free survival of the 
selected treatment histories, once controlled for main confounding factors at baseline. We 
compared treatment costs associated with the therapeutic pathway categories using multivariate 
linear regression.  
We took account of the enrolment period in which each patient entered the cohort as an 
indicator of the advancements that had occurred in HAART technology over time. The other 
explanatory variables included in the regression analyses were drawn from both patient and 
provider characteristics. Among the former set of covariates there were the following attributes: 
demographic characteristics: gender and age at enrolment;  
clinical and immuno-virological parameters: CDC stage (clinical stage as classified by the 
US Centers for Disease Control and Prevention), CD4 T-lymphocyte cells count and plasma 
viral load (main predictors of prognosis) at baseline, hepatitis C coinfection;  
follow-up information: inpatient admissions, new AIDS Defining Events occurred after 
starting therapy, viral load tests resulting in detectable viremia after therapy initiation (which 
signal for virological failures of therapies, or at least blips, intermittent episodes of high level 
viremia); and 
behavioral attributes: HIV exposure category.  
The latter group of covariates included:  
structural characteristics: provider size measured by the number of ward beds, how much 
specialized on HIV care the provider is, as indicated by the number of HIV+ subjects out of all 
patients admitted to the ward/clinic, and internal availability of advanced diagnostic procedures 
(genotypic assessment); and  
behavioral attributes: number of national and international publications either as authors or as 
research group participants, and participation in national and international multi-center clinical 
studies – which both stand for the amount of research activity going on in the ward/clinic and 
  8proxies for clinicians knowledge updating (publication activity asking for more active 
involvement) – as well as how much each provider focuses on a few standard treatment patterns, 
or spreads over a variety of pathways (measured by means of a Herfindahl-Hirschman 
concentration index), as a proxy of the intensity of communications, influences and coordination 
among clinicians operating in the same ward/clinic.  
Main sample descriptive statistics and pairwise correlations of continuous and binary 





5.1. Sequence analysis of therapeutic switches 
 
We ran optimal alignment on the 619 different therapeutic sequences in our sample, using the 
various specifications for inter-element weights described in the Methods: transition probabilities 
between therapies, pharmacological and clinical dissimilarities and, as a benchmark, the simple 
edit distance with uniform weights. After running optimal alignment, we grouped our sequences 
based on the resulting distance matrices. We compared the fit of clustering from four common 
hierarchical algorithms: single, complete, average and Ward's linkages. We chose weights 
derived from clinical considerations and the average linkage method as the solution that best fit 
the data.  
 
Table 2 Therapeutic sequences clustering: leader sequences and number of patients in each cluster. 
Cluster  Sequence
a  N %  Cum
1  2NRTI+1PI   2NRTI+1PI
b  1  342 44.99 44.99
2  2NRTI+1PI   2NRTI+1PI   2NRTI+1PI  249  8.35  53.34
3 2NRTI  238  7.98  61.31
4  2NRTI   2NRTI+1PI  134  4.49  65.81
5  2NRTI   2NRTI   2NRTI+1NNRTI  112  3.75  69.56
6  2NRTI+1PI   2NRTI+1PI   2NRTI+1PI   2NRTI+1PI  88  2.95  72.51
7  2NRTI+1PI   2NRTI   2NRTI+1PI  88  2.95  75.46
8  2NRTI+1PI   3NRTI  86  2.88  78.34
9-30 Others  646  21.67  100
  Total  2 983  100 
a Substitution costs based on clinical and pharmacological differences between drug combinations were set by 
expert judgment. Factors guiding expert opinion included: number and drug class of the agents in the mix; 
expected tolerability of each drug combination; unusual combinations not recommended by therapeutic 
guidelines; mono and dual therapies which were the standard in the pre-HAART era, but are now considered 
under-performing compared to HAART, and are no longer recommended for treatment; combinations with 
b NRTI = nucleoside reverse transcriptase inhibitor, PI = protease inhibitor, NNRTI = nonnucleoside reverse 
transcriptase inhibitor. Since the class of NtRTIs is similar to the NRTIs and includes so far only one 
antiretroviral agent, we included it in the latter. 
 
In order to get small and tightly connected clusters of therapeutic sequences, we set the cut-
off value used to form new clusters at a relatively low level of inconsistency. We obtained 238 
clusters, for which we chose the central sequences (the medoids of the clusters) as the 
representative objects. We then ran the partitioning around medoid algorithm on the extracted 
  9sequences to get eventually 30 clusters with their respective leaders (Table 2). Within and 
between cluster distances were compared with a t-test; the significance testing procedure was an 
application of the Jackknife technique. The hypothesis of equal distances within and between 
clusters was rejected at the .01 confidence level; data had been grouped into quite homogeneous 
and well separated clusters.  
As illustrated in Table 2, in most cases the first line treatment was either a dual therapy with 
two NRTIs or already a HAART regimen containing one PI. Most of the patients starting with a 
dual therapy switched to HAART afterwards – to a PI-containing or an NNRTI-containing 
regimen – either directly, or after having tried various dual combinations. Probably due to the 
low tolerability of PI-containing regimens, or just to the availability of an expanding range of 
molecules over time, in many clusters we observe several switches among PI-containing 
therapies, while in others an NNRTI-regimen or a maintenance therapy with 3 NRTIs was 
preferred.  
Mega-HAART with more than three drugs, and HAART with two PIs administered in 
association, together with anomalous regimens, were usually initiated as salvage therapies (that 
is, after other regimens had been tried unsuccessfully). The few occurrences of patients sticking 
to (or even turning again to) mono therapies with one NRTI are to be considered exceptional, 
whereas cases of subjects switching at least temporally from HAART to dual therapies were 
more frequent. 
Sequence analysis conducted on combination therapies shows that the adoption of the new 
powerful drug combinations (HAART) proceeded more slowly than expected from their 
technological superiority, and the emergence of a standard of care, as a coherent pattern of 
treatment with few alternative strategies, was far from predictable and straightforward. 
 
 
5.2. Patient and supply-side factors associated to different therapeutic paths 
 
The previous analysis has revealed a significant heterogeneity in individual's treatment histories. 
This is in sharp contrast with the apparent advantages of HAART technology and cannot be 
explained as a consequence of patient heterogeneity alone. In order to shed some light on the 
determinants of divergent therapeutic paths, we performed an exploratory analysis looking for 
supply-side factors associated with different treatment strategies. The aim of the exercise was to 
gain some insights into structural and behavioral characteristics of the providers, if any, affecting 
therapeutic choices together with patient attributes. 
We selected as the base choice category of the multinomial logit model estimates the 
therapeutic sequence where an initial HAART (a single PI or NNRTI containing regimen) was 
followed by a new HAART formulation, and we labeled it simply HAART. Relative to this 
standard, which accounts for 45% of our sample, we identified two opposite pathways, one in 
which the individual never started HAART, but instead continued a dual therapy, and another in 
which the subject often switched to HAART only after trying several dual combinations 
(accounting together for 16% of the sample), which we called a pre-HAART and a switching-to-
HAART treatment pattern, respectively. All other patterns, characterized by less straightforward 
histories, with many therapy switches, and sometimes quite uncommon drug combinations, were 
grouped into a single residual category.  
Regression results are shown in Table 3. Individual characteristics were selected according to 
the clinical literature on factors driving therapeutic choices (as summarized, for instance, by the 
  10U.S. Treatment Guidelines). Among demographic factors we found that women were more likely 
than men to start with a dual therapy and to follow an idiosyncratic therapeutic path. This result 
can be associated to women being more likely than men to discontinue antiretroviral therapies 
due to toxicity and to women starting AZT mono therapy during pregnancy. Early stages of the 
disease and a less aggressive infection (higher CD4 cells count and lower viral load level)
1, as 
well as Hepatitis-C co-infection (HCV+), were associated to a greater probability of starting and 
remaining on a dual therapy compared to HAART. The number of virological treatment failures 
(episodes of detectable viremia after therapy initiation) was positively associated with having a 
non standard treatment history, both because they were more frequent among patients following 
a pre-HAART therapy, and usually led to therapy switching toward different and sometimes 
unusual combinations. 
These factors all relate to patient heterogeneity in baseline characteristics and response to 
therapy, and obviously play a major role in determining treatment strategies. We were interested 
in understanding whether there is also a place for explaining factors associated to the evolution 
of the technology and the characteristics of providers as potential adopters. First of all, the 
enrolment period was strongly associated with treatment history: the marginal effect of entering 
the cohort during the second round of enrolments on the probability of ending up with a standard 
treatment path was 0.22. Those enrolled in the year 2000 or after were less likely to follow a non 
standard pattern of therapies due both to the diffusion of HAART as a technological standard and 
to the shorter follow-up time. This, in turn, may indicate that the gradual advancements in 
HAART technology have had an appreciable impact on the probability of adoption of the new 
standard of care.  
In addition, the number of scientific publications was negatively associated with the 
probability of staying on dual therapies instead of switching to HAART (the effect of one 
standard deviation increase from the mean number of scientific publications on the probability of 
being in our base outcome category was 0.06). This result confirms the importance for the 
diffusion of innovations of channels allowing the open communication of productive knowledge 
within the medical profession.  
Finally, high concentration levels on common treatment strategies among practitioners 
belonging to the same clinical center were less likely to lead to under-performing pathways with 
dual therapies instead of HAART or to idiosyncratic therapeutic histories. We observed a 
positive effect of 0.22 on the probability of following a standard therapeutic pattern for one 
standard deviation increase from the mean of the Herfindahl-Hirschman index. High 
concentration of therapeutic strategies at the provider level can be considered an indicator of the 
intensity of coordination and exchange of information among local practitioners. This finding 
points to the impact of bureaucratic organizational mechanisms, interacting with doctors' 
professional autonomy, on the diffusion of innovations. 
 
                                                 
1 We always took the square root of CD4 cell counts, and the log base ten of plasma HIV-RNA levels to be included 
in our regression models, in order to account for the skewed distributions of these variables.  
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(0.008) (0.007) (0.005)
Specialization in HIV care  1.636  1.084  0.916 
(0.837) (0.515) (0.278)
Genotypic assessment  0.880  0.795  1.000 
(0.288) (0.242) (0.188)




Multi-center studies   1.021  0.992  1.009 
(0.017) (0.015) (0.010)




(0.009)  (0.008) (0.005)
N 2 163
Log-likelihood      -2 209.59
Likelihood-Ratio chi-squared (36)  700.23
*** 
a Relative Risk Ratio. Standard errors in parentheses. 
*p < 0.10   
**p < 0.05   
***p < 0.01 5.3. Health outcomes and costs of different therapeutic paths 
 
Having examined the emergence of new therapeutic strategies coming with the diffusion of 
innovative health technologies we turned to the analysis of the associated health outcomes. In 
particular, we were interested in understanding whether departures from the identified standard of 
care, resulting from autonomous medical decisions, led to inferior outcomes in terms of clinical 
endpoints.  
 
Table 4 Cox proportional hazards model estimates of time to AIDS/death on patient characteristics and therapeutic 
path. 
Time to AIDS/death  HR
a 
CD4+ (square root cells/mm
3) 0.939
*** 
  (0.012) 
HIV-RNA (log10 copies/ml)  1.304
*** 
  (0.124) 
CDC stage B  1.241 
  (0.212) 
HCV+  0.798 





  (0.090) 
Heterosexual 0.319
*** 
  (0.072) 
Other 0.585 
  (0.192) 
Woman 1.046 
  (0.185) 
Age (years)  1.028
*** 
  (0.009) 
Treatment pattern   
pre-HAART 1.597
* 
  (0.388) 
switching-to-HAART 0.865 
  (0.207) 
Other 0.590
*** 
  (0.099) 
(reference: HAART)   
N   2 377 
Log-likelihood -1  413.05 
Likelihood-Ratio chi-squared (12)  134.52
*** 
a Hazard ratios. Standard errors in parentheses. 
*p < 0.10   
**p < 0.05   
***p < 0.01   
b Reference category: Intravenous drug user
   
 
Table 4 reports Cox proportional hazards estimates of time to full-blown AIDS or death adjusted 
for clinical and immuno-virological parameters at baseline, Hepatitis C co-infection, exposure 
category, gender, and age at enrolment (see, e. g., Egger et al., 1997), together with the treatment 
pattern followed by each subject in the sample (patient diagnosed with AIDS at enrolment were of 
course excluded from the analysis).  There was some evidence of patients on dual therapies being more likely to progress to full-
blown AIDS or death than those in our reference category (starting HAART as first line regimen 
and switching therapy at most once), while subjects in the residual group, with non-standard 
treatment histories, were progressing to AIDS/dying at a lower rate than those in the comparison 
group (hazard ratios equal to 1.60 and .59, respectively). Older individuals had a higher hazard rate, 
as expected, as well as more debilitated patients (with lower CD4 cells count and higher viral load). 
Exposure category was also related to disease progression and survival.  
An important caveat concerns the limited length of the study: we observed six years in the life of 
the cohort, which provide only medium-run evidence of disease progression for what is nowadays 
becoming a chronic infection. 
Cohort subjects with non-standard treatment histories, are experiencing better clinical outcomes 
than those following a standard treatment path. In highly complex technological enviroments with 
moving technologies and strong uncertainty, decentralized professional decision making results in 
better outcomes in the management of technological innovations.  
 
Table 5 OLS estimates of log average annual costs on patient characteristics and therapeutic path 
Log average annual costs  Coefficient
a
CD4+ (square root cells/mm
3) -0.023
*** 
  (0.002) 
HIV-RNA (log10 copies/ml)  0.080
*** 
  (0.019) 
HCV+ -0.062
** 
  (0.028) 
Detectable viremia episodes  0.062
*** 
  (0.007) 
Square of detectable viremia episodes  -0.002
*** 
  (0.000) 
New AIDS Defining Events  0.163
*** 
  (0.048) 
Square of New AIDS Defining Events  -0.032
*** 
  (0.012) 
Inpatient admissions  0.237
*** 
  (0.025) 
Enrolment Period II  0.215
*** 
  (0.049) 









(reference: HAART)   
Constant 8.382
*** 
  (0.114) 
N  2 818 
F(44, 2 773)  28.31
*** 
R-squared  0.316 
a Standard errors in parentheses. 
*p < 0.10   
**p < 0.05   
***p < 0.01
   
 
  14We integrated the previous analysis of health outcomes with an examination of the costs incurred 
in treating a sub-sample of 2 818 patients, for which full baseline and follow-up information was 
available. In a multivariate regression of log annual direct health costs (yearly averages over 
patients' follow-up period in 1997 constant prices) the OLS estimated coefficient of therapeutic 
pathway category for patients remaining on dual therapy was negative and significant
2. The 
coefficient of the treatment category including subjects who switched to HAART after following a 
dual therapy, was still negative (although the absolute value was much lower) but not statistically 
significant, while that of the residual pattern category was positive and only slightly significant.  
Regressors included controls for baseline medical conditions (immunological and virological 
values at baseline) and follow-up adverse events (virological treatment failures, new AIDS Defining 
Events occurring in the course of therapy, and number of inpatient admissions) that might affect 
total health costs independently of antiretroviral therapy administration. Coefficient estimates for all 
independent variables are reported in Table 5 with White-robust standard errors to account for 
heteroskedasticity. In the regression we also controlled for health provider using a stepwise 
procedure (coefficients are omitted from the results). 
Estimates of the annual costs in the log scale, evaluated at the mean of the continuous covariates, 
for a HCV-negative individual enrolled during the first enrolment period (with no adjustment for 
health provider) were equal to 8.275, 7.802, 8.227, and 8.324, corresponding to median raw costs of 
3 924 euro for the reference group, and 2 445, 3 739, and 4 122 euro for the other therapeutic 
patterns, respectively. 
Suboptimal treatment patterns (i.e., persistent dual therapies) led to worse clinical endpoints and 
were associated to lower health expenditures, whereas non-standard therapeutic histories favored 





In this study we contributed to the analysis of medical innovations highlighting the evolving nature 
of technologies themselves, along with the interplay of the different actors involved at the 
individual or more aggregate level, which together led to complex patterns of adoption and 
implementation in our empirical setting. 
Sequence analysis methodology allowed us to describe in detail HIV-positive patients' whole 
treatment histories, privileging an analytic representation to a synthetic focus on specific features of 
HIV therapies. We found that the high variety observed in therapeutic paths can be only partly 
explained by observable patient characteristics. An important role is also played by continuous 
technological progress and providers' activities and routines. Still, a major component of treatment 
heterogeneity seems to be related to the idiosyncratic behavior of every single physician, the 
individual patient reaction to treatment, and the interaction between patient and provider's medical 
staff.  
Standardization seems to have occurred at a lesser extent than we might have predicted looking 
at scientific advances and leading opinions. Treatment guidelines, which sometimes lag behind the 
introduction of innovations, do not (and, actually, cannot) cover the entire set of therapy 
                                                 
2 Health care expenditure data are typically highly skewed and not normally distributed. A small number of large cost 
observations can have a critical impact on the size of the estimated parameters and their significance when regressing 
raw costs data on potentially related covariates. Logarithmically transforming health care expenditure data can reduce 
the influence of outlier observations and make traditional statistical assumptions more plausible. In our data the mean of 
the raw annual costs was 7 310 euro, while the median was 5 879 euro, and the skewness 41.57. That is, right tail 
skewness was substantial, with the median being much smaller than the mean, and the measure of skewness being 
positive and large. However when cost data were log-transformed, skewness fell close to zero – actually, it was slightly 
negative (-1.59, variance = .70). 
  15administration issues. Even on those topics covered by treatment guidelines, clinical decisions have 
been taken more with regard to the practical circumstances faced by medical professionals in their 
everyday activity, and to the local practice adopted by the clinical center. So far heterogeneity 
among treatment pathways has proved beneficial from the effectiveness side, and has not led to 
significantly higher health expenses. 
The variability observed in HAART adoption patterns across clinical centers, both in terms of 
the pace of adoption of new drugs and the preference accorded to specific combination therapies 
and/or their sequences, resulted in a slower overall process of adoption of this new technology than 
would be expected from its highly improved efficacy. This effect may have been emphasized by an 
underlying inertia, coming in this case from a conservative strategy of prosecution along the lines of 
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  18Appendix Sample descriptive statistics and correlations. 
   Woman  HCV+  Enrolment Geno-assay CD4+ HIV-RNA Failures ADEs Inpatient Age  Size  HIV  care Publications Studies HHI 
Woman   1.000                         
HCV+   -0.063 1.000                       
                   
                 
                
              
            
           
         
        
      
    
  
Enrolment period II  0.021 -0.159 1.000
Genotypic assessment  0.129 -0.045 0.109 1.000
CD4+ (square root cells/mm
3)  0.063 0.053 -0.190 -0.016 1.000
HIV-RNA (log10 copies/ml)  -0.103 -0.036 0.174 -0.007 -0.406 1.000
Detectable viremia episodes  -0.017 -0.025 -0.308 -0.102 0.043 0.045 1.000
New ADEs  -0.019 0.003 -0.042 0.028 -0.188 0.119 0.030 1.000
Inpatient episodes  0.004 0.030 -0.011 0.059 -0.278 0.207 0.060 0.587 1.000
Age  -0.162 -0.105 0.051 -0.029 -0.140 0.089 -0.018 -0.005 0.040 1.000
Size  -0.026 -0.037 -0.071 0.176 0.072 -0.108 0.117 0.003 0.051 -0.053 1.000
Specialization in HIV care  0.146 -0.084 0.122 0.109 -0.097 0.104 0.031 0.028 0.033 -0.046 -0.105 1.000
Publications  -0.039 -0.073 0.030 -0.180 -0.005 -0.076 0.191 -0.037 0.008 0.006 0.082 0.188 1.000
Multi-center studies  0.010 -0.063 0.055 -0.052 0.027 -0.065 0.005 -0.001 -0.040 -0.008 0.122 -0.100 -0.071 1.000 
HHI  0.082 -0.021 0.187 0.327 -0.138 0.128 -0.257 0.043 0.025 -0.049 -0.180 0.301 -0.138 -0.201 1.000 
N  2 983 2 983 2 983 2 983 2 976 2 837 2 983 2 983 2 983 2 983 2 983 2 566 2 489 2 482 2 983 
Min  0.00 0.00 0.00 0.00 0.00 1.30 0.00 0.00 0.00 0.00 0.00 0.01 2.00 2.00 10.61 
Max  1.00 1.00 1.00 1.00 41.90 7.15 37.00 8.00 12.00 98.00 59.00 0.97 84.00 25.00 76.33 
Mean  0.31 0.38 0.20 0.14 17.14 4.55 5.03 0.13 0.40 36.93 24.99 0.32 16.75 11.34 26.61 
SD              7.36 0.91 5.64 0.53 0.91 8.57 10.69 0.20 15.82 5.66 12.55 
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